Yusuke Echigoya
Has grant
Assistant Professor
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Yusuke Echigoya is an Assistant Professor at Nihon University in Japan. His research focuses on virology and neuromuscular diseases, with recent articles investigating antiviral therapies for Japanese Encephalitis Virus and innovative treatments for Duchenne muscular dystrophy. Additionally, he conducts research on therapies for facioscapulohumeral muscular dystrophy, contributing to advancements in exon skipping techniques.
Recent Grants
Grant: Close
Development of therapeutic oligonucleotides as antiviral compounds
Open Date: 2017-01-01
Close Date: 2021-01-01
Grant: Close
Multiple exon skipping therapy in a transgenic pig model of muscular dystrophy
Open Date: 2015-01-01
Close Date: 2017-01-01
Articles (4)
RNase H-dependent gapmer antisense oligonucleotides (ASOs) are a promising therapeutic approach via sequence-specific binding to and degrading target RNAs. However, the efficacy and mechanism of antiviral gapmer ASOs have remained unclear. Here, we investigated the inhibitory effects of gapmer ASOs containing locked nucleic acids (LNA gapmers) on proliferating a mosquito-borne flavivirus, Japanese encephalitis virus (JEV), with high mortality. We designed several LNA gapmers targeting the 3′ untranslated region of JEV genomic RNAs. In vitro screening by plaque assay using Vero cells revealed that LNA gapmers targeting a stem-loop region effectively inhibit JEV proliferation. Cell-based and RNA cleavage assays using mismatched LNA gapmers exhibited an underlying mechanism where the inhibition of viral production results from JEV RNA degradation by LNA gapmers in a sequence- and modification-dependent manner. Encouragingly, LNA gapmers potently inhibited the proliferation of five JEV strains of predominant genotypes I and III in human neuroblastoma cells without apparent cytotoxicity. Database searching showed a low possibility of off-target binding of our LNA gapmers to human RNAs. The target viral RNA sequence conservation observed here highlighted their broad-spectrum antiviral potential against different JEV genotypes/strains. This work will facilitate the development of an antiviral LNA gapmer therapy for JEV and other flavivirus infections.
Year:
2023
Year:
2022
Year:
2021
Year:
2020
Collaborators (3)
Joe Kornegay
Professor; Director
Texas A&M University
Takuya Itou
-
William Duddy
University of Ulster
Make your next move.
Prepare your application
Review drafts before you send them.